MarketPulse

CAR T-cell

2 articles
BenzingaBenzinga··Prnewswire

Cell Therapies Graduate to Mass Production as Market Eyes $8.2B Prize

Cell therapy companies achieve major manufacturing and clinical milestones, positioning sector for explosive growth as global market targets $8.2 billion by 2026.
MESOFATEFBLGLGVNbiotechclinical trials
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Oncology-Focused Arcellx in $7.8B Cash Deal

Gilead acquires oncology firm Arcellx for $7.8 billion in cash, adding CAR T-cell cancer therapy to its pipeline. Deal expected to close Q4 2024.
GILDACLXacquisitionM&A